The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen.
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir / P. Cicconi, M. Bongiovanni, S. Melzi, F. Tordato, A. d'Arminio Monforte, T. Bini. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - 24:3(2004), pp. 284-285.
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir
A. d'Arminio MonfortePenultimo
;
2004
Abstract
The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0924857904001530-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
36.1 kB
Formato
Adobe PDF
|
36.1 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
